Pentixapharm Holding AG Secures FDA Fast Track for Diagnostic Candidate

Berlin-based Pentixapharm Holding AG has received FDA Fast Track designation for its diagnostic candidate, [⁶⁸Ga]Ga-PentixaFor. This progress focuses on the subtyping of primary aldosteronism in adults. The Fast Track process allows for enhanced interaction with the FDA during the development stages, potentially streamlining the regulatory review process if necessary conditions are satisfied.

The designation follows the FDA's clearance of the company's Phase 3 PANDA study Investigational New Drug application. The company's ongoing rights issue remains unchanged, with the subscription period concluding on July 21, 2026.

It’s important to note that Fast Track designation doesn't imply immediate approval and the regulatory process continues. The public must remain aware of the limitations associated with this designation.